Neratinib

Brand names: Nerlynx · Active ingredient: Neratinib Maleate Anhydrous

In short: NERLYNX as a single agent is indicated for the extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer, to follow adjuvant trastuzumab based therapy . NERLYNX in combination with capecitabine is indicated for the treatment

Forms & strengthsTablets: 40 mg neratinib (equivalent to 48.31 mg of neratinib maleate). Film-coated, red, oval shaped and debossed with 'W104' on one side and plain on the other side.
LabelPuma Biotechnology, Inc.
Label updatedJul 06, 2026

What is Neratinib used for?

NERLYNX as a single agent is indicated for the extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer, to follow adjuvant trastuzumab based therapy

.

NERLYNX in combination with capecitabine is indicated for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting

.

Neratinib dosage

When not using dose escalation

,

administer antidiarrheal prophylaxis during the first 56 days of treatment and initiate with the first dose of NERLYNX

.

Instruct patients to take loperamide as directed in

Table 1. Titrate loperamide to 1–2 bowel movements per day.

Time on NERLYNX | Loperamide Dose and Frequency

Weeks 1–2 (days 1–14) | 4 mg three times daily

Weeks 3–8 (days 15–56) | 4 mg twice daily

Weeks 9–Discontinuation of NERLYNX | 4 mg as needed, not to exceed 16 mg per day; titrate dosing to achieve 1–2 bowel movements per day

If diarrhea occurs despite prophylaxis, treat with additional antidiarrheals, fluids and electrolytes as clinically indicated. NERLYNX dose interruptions and dose reductions may also be required to manage diarrhea

.

Extended Adjuvant Treatment of Early-Stage Breast Cancer

The recommended dose of NERLYNX is 240 mg (six tablets) given orally once daily, with food, continuously until disease recurrence or for up to one year.

Advanced or Metastatic Breast Cancer

The recommended dose of NERLYNX is 240 mg (six tablets) given orally once daily with food on Days 1–21 of a 21-day cycle plus capecitabine (750 mg/m

2given orally twice daily) on Days 1–14 of a 21-day cycle until disease progression or unacceptable toxicities.

Dose Escalation

A two-week dose escalation for NERLYNX may be considered instead of starting at the 240 mg daily dose for patients with early-stage breast cancer and metastatic breast cancer, as described in

Table 2

.

Time on NERLYNX | NERLYNX Dose

Week 1 (days 1–7) | 120 mg daily (three 40 mg tablets)

Week 2 (days 8–14) | 160 mg daily (four 40 mg tablets)

Week 3 and onwards | 240 mg daily (six 40 mg tablets, recommended dose)

If diarrhea occurs, treat with antidiarrheal medications, fluids, and electrolytes as clinically indicated. NERLYNX dose interruptions and dose reductions may also be required to manage diarrhea

.

Administration Instructions

Instruct patients to take NERLYNX at approximately the same time every day. NERLYNX tablets should be swallowed whole (tablets should not be chewed, crushed, or split prior to swallowing).

If a patient misses a dose, do not replace missed dose, and instruct the patient to resume NERLYNX with the next scheduled daily dose.

NERLYNX dose modification is recommended based on individual safety and tolerability. Management of some adverse reactions may require dose interruption and/or dose reduction as shown in

Table 3to

Table 6.

Discontinue NERLYNX for patients with adverse reactions that fail to recover to Grade 0–1 or baseline, with toxicities that result in a treatment delay >3 weeks, or if unable to tolerate 120 mg daily. …

How to take Neratinib — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (

Patient Information).

Diarrhea

Inform patients that NERLYNX has been associated with diarrhea, which may be severe in some cases.

When not using dose escalation, instruct patients to initiate antidiarrheal prophylaxis with the first dose of NERLYNX.

When using dose escalation, instruct patients to initiate 2 weeks of lower dose NERLYNX prior to receiving the recommended full dose of NERLYNX.

Instruct patients to maintain 1–2 bowel movements per day and on how to use antidiarrheal treatment regimens.

Advise patients to inform their healthcare provider immediately if severe (≥Grade 3) diarrhea or diarrhea associated with weakness, dizziness, or fever occurs during treatment with NERLYNX

.

Hepatotoxicity

Inform patients that NERLYNX has been associated with hepatotoxicity which may be severe in some cases.

Inform patients that they should report signs and symptoms of liver dysfunction to their healthcare provider immediately

.

Embryo-Fetal Toxicity

Advise females to inform their healthcare provider if they are pregnant or become pregnant. Inform female patients of the risk to a fetus and potential loss of the pregnancy

. …

Warnings & precautions

Do not take this medicine if: None.

Severe diarrhea and sequelae, such as dehydration, hypotension, and renal failure occurred during treatment with NERLYNX. Diarrhea was reported in 95% of NERLYNX-treated patients in ExteNET, a randomized placebo-controlled trial in the extended adjuvant setting who were not required to receive antidiarrheal prophylaxis. In the NERLYNX arm, Grade 3 diarrhea occurred in 40% and Grade 4 diarrhea occurred in 0.1% of patients. The majority of patients (93%) had diarrhea in the first month of treatment, the median time to first onset of Grade ≥3 diarrhea was 8 days (range, 1–350), and the median cumulative duration of Grade ≥3 diarrhea was 5 days (range, 1–139)

.

Diarrhea was reported in 83% of NERLYNX plus capecitabine treated patients in NALA, a randomized placebo-controlled trial in the metastatic breast cancer setting who were required to receive anti-diarrheal prophylaxis in the first 21-day cycle. The majority of patients (70%) had diarrhea in the first 21 days of treatment, the median time to first onset of Grade ≥3 diarrhea was 11 days (range, 2–728) and the median cumulative duration of Grade ≥3 diarrhea was 3 days (range, 1–21). In the NERLYNX plus capecitabine arm, Grade 3 diarrhea occurred in 24% of patients

.

Antidiarrheal prophylaxis has been shown to lower the incidence and severity of diarrhea. Instruct patients to initiate antidiarrheal prophylaxis with loperamide along with the first dose of NERLYNX and continue during the first 56 days of treatment; after day 56, titrate dose to achieve 1–2 bowel movements per day and not to exceed 16 mg loperamide per day

. Consider adding other agents to loperamide as clinically indicated

.

Alternatively, a 2-week NERLYNX dose escalation approach prior to initiation of the recommended treatment regimen with NERLYNX can also be considered for diarrhea management

. …

Neratinib side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

Diarrhea

Hepatotoxicity

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Extended Adjuvant Treatment of Early-Stage Breast Cancer

ExteNET

The data described below reflect the safety data of NERLYNX as a single agent in ExteNET, a multicenter, randomized, double-blind, placebo-controlled study of NERLYNX within 2 years after completion of adjuvant treatment with trastuzumab-based therapy in women with HER2-positive early-stage breast cancer. Patients who received NERLYNX in this trial were not required to receive any prophylaxis with antidiarrheal agents to prevent the NERLYNX-related diarrhea. Patients were treated with 240 mg of NERLYNX given orally once daily with food, continuously until disease recurrence or for up to one year. The median duration of treatment was 11.6 months in the NERLYNX arm and 11.8 months in the placebo arm. The median age was 52 years (60% were ≥50 years old, 12% were ≥65 years old); 81% were Caucasian, 3% Black or African American, 14% Asian, and 3% other. A total of 1408 patients were treated with NERLYNX. …

Drug interactions

Table 10includes drug interactions that affect the pharmacokinetics of neratinib.

AUC=Area Under Curve; C

max=Maximum Concentration

Gastric Acid Reducing Agents

Clinical Impact | Concomitant use of NERLYNX with a proton pump inhibitor (PPI), H

2-receptor antagonist, or antacid may decrease neratinib AUC

,

which may reduce NERLYNX activity.

Prevention or Management

| Avoid concomitant use of PPIs.

Separate administration of NERLYNX at least 2 hours before or 10 hours after the H

2-receptor antagonist dose.

Separate administration of NERLYNX by at least 3 hours after antacids.

Strong CYP3A4 Inhibitors

Clinical Impact | Concomitant use of NERLYNX with a strong CYP3A4 inhibitor increased neratinib C

maxand AUC

, which may increase the risk of NERLYNX toxicity.

Prevention or Management | Avoid concomitant use of NERLYNX with strong CYP3A4 inhibitors.

P-gp and Moderate CYP3A4 Dual Inhibitors

Clinical Impact | Concomitant use of NERLYNX with a P-gp and moderate CYP3A4 dual inhibitor may increase neratinib C

maxand AUC

, which may increase the risk of NERLYNX toxicity.

Prevention or Management | Avoid concomitant use of NERLYNX with P-gp and moderate CYP3A4 dual inhibitors. …

About this medicine

NERLYNX (neratinib) immediate release, film-coated tablets for oral administration contain 40 mg of neratinib, equivalent to 48.31 mg neratinib maleate. Neratinib is a member of the 4-anilino quinolidine class of protein kinase inhibitors. The molecular formula for neratinib maleate is C

30H

29ClN

6O

3•C

4H

4O

4and the molecular weight is 673.11 Daltons. The chemical name is (E)-N-{4-[3-chloro-4-(pyridin-2-yl methoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl}-4-(dimethylamino)but-2-enamide maleate, and its structural formula is:

Neratinib maleate is an off-white to yellow powder with pK

as of 7.65 and 4.66. The solubility of neratinib maleate increases dramatically as neratinib becomes protonated at acidic pH. Neratinib maleate is sparingly soluble at pH 1.2 (32.90 mg/mL) and insoluble at approximately pH 5.0 and above (0.08 mg/mL or less).

Inactive ingredients: Tablet Core: colloidal silicon dioxide, mannitol, microcrystalline cellulose, crospovidone, povidone, magnesium stearate, and purified water. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID d1e41dcf-e82a-47c2-a0ad-6c6eef621834. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate